Is Ombitasvir + Paritaprevir + Ritonavir registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Ombitasvir + Paritaprevir + Ritonavir.

Is Ombitasvir + Paritaprevir + Ritonavir approved by the US FDA?

Drugs@FDA lists 1 application product line for Ombitasvir + Paritaprevir + Ritonavir, including TECHNIVIE (Discontinued).

Is Ombitasvir + Paritaprevir + Ritonavir authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Ombitasvir + Paritaprevir + Ritonavir.

Active substances

Ombitasvir + Paritaprevir + Ritonavir

SFDA 1
US FDA 1
EMA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
VIEKIRAX film-coated tablet	12.5, 50, 75 mg	Film-coated tablet · Oral use	56 Blister	SAR 81463.75	NCE · Prescription	ABBVIE	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
TECHNIVIE	12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	tablet · oral	ABBVIE	Discontinued	24 Jul 2015

EMA European Union — centrally authorised medicines

Viekirax AbbVie Deutschland GmbH & Co. KG · Withdrawn · authorised 14 Jan 2015 · ATC J05AP53

Therapeutic indication (EMA)

Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.